Gerald Clarke | 08/12/2013
When GE Healthcare recently withdrew their Fetal Bovine Serum (FBS) products due to non-conformancies, it highlighted the real need for product safety and traceability practices in the field. Pharma IQ spoke to Rosemary Versteegen, CEO of the International Serum Industry Association about this case and what the industry can learn from it.
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Sustainability and Inclusivity in Pharma Manufacturing: Insights from AstraZeneca’s People Hub
2024-12-11
Upcoming Events
Pharmaceutical Launch Excellence Summit
2 - 3 December, 2025
UK
Register Now |
View Agenda |
Learn More